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ABSTRACT 17 
Treatment of HIV patients co-infected with tuberculosis (TB) is challenging due to drug-drug 18 
interactions (DDIs) between antiretrovirals (ARVs) and anti-TB drugs.  The aim of this study 19 
was to quantify the effects of cobicistat (COBI), or ritonavir (RTV), in modulating DDIs 20 
between darunavir (DRV) and rifampicin (RIF) in a human hepatocyte-based in vitro model.  21 
Human primary hepatocyte cultures were incubated with RIF alone, or in combination with 22 
either COBI or RTV for three days, followed by co-incubation with DRV for one hour.  23 
Resultant DRV concentrations were quantified by HPLC-UV, and the apparent intrinsic 24 
clearance (CLint.app.) of DRV was calculated.  Both RTV and COBI lowered RIF-induced 25 
increases in CLint.app. in a concentration-dependent manner.  Linear regression analysis showed 26 
that log10 RTV and log10 COBI concentrations were associated with percentage inhibition of RIF-27 
induced elevations in DRV CLint.app. β = -94 (95% CI = -108 to -80; P=0.0001), and β = - 61 28 
(95% CI = -73 to -49; P=0.0001), respectively.  RTV was more effective in lowering 10 µM 29 
RIF-induced elevations in DRV CLint.app. (EC50 = 1.54 µM) than COBI (EC50 = 2.58 µM).  30 
Incubation of either RTV, or COBI, in combination with RIF was sufficient to overcome RIF-31 
induced elevations in DRV CLint.app., with RTV more potent than COBI.  These data provide the 32 
first in vitro experimental insight into DDIs between RIF and COBI-boosted or RTV-boosted 33 
DRV, and will be useful to inform physiologically-based pharmacokinetic models to aid in 34 
optimising dosing regimens for the treatment of HIV-TB patients receiving concomitant ARVs 35 
and anti-TB drugs.36 
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INTRODUCTION 37 
Approximately 25% of human immunodeficiency virus-1 (HIV)-infected patients worldwide are 38 
co-infected with Mycobacterium tuberculosis (1, 2), accounting for 390,000 deaths in 2014 (3).  39 
Clinical management of HIV-tuberculosis (HIV-TB) patients presents significant challenges, 40 
especially in resource-limited settings (2, 4), where virological failure or intolerance to first-line 41 
antiretroviral therapy requires the use of HIV protease inhibitors (PIs) (5).  PIs largely undergo 42 
phase I metabolism by cytochrome p450 3A4 (CYP3A4), and are also substrates of P-43 
glycoprotein (P-gp; ABCB1) (6).  Consequently, PIs are commonly administered in combination 44 
with pharmacokinetic (PK) “boosters” such as ritonavir (RTV) or cobicistat (COBI), which act 45 
by inhibiting CYP3A4-mediated PI metabolism and P-gp-mediated PI efflux, thereby improving 46 
the PK profile of PIs by prolonging PI half-life, and increasing PI bioavailability (7-9). 47 
 48 
Rifampicin (RIF) is an essential component of short-course anti-TB treatment regimens 49 
(2, 10); however, RIF is also a potent inducer of the expression and activity of several metabolic 50 
enzymes – including CYP3A4 (11). Co-administering RIF with PIs can result in clinically-51 
significant drug-drug interactions (DDIs), whereby PI bioavailability may be significantly 52 
reduced (>75%) (10, 12-14).  Consequently, administering standard-doses of RTV-boosted PIs 53 
to HIV-TB patients receiving RIF is contraindicated under the current World Health 54 
Organisation (WHO) guidelines (15).  The search for effective second-line therapeutic options 55 
for the treatment of HIV-TB co-infected patients is therefore a research priority (16). 56 
 57 
Darunavir (DRV) is chiefly metabolised by CYP3A4 (17) and co-administration of a 58 
low-dose of either RTV or COBI together with DRV increases DRV systemic bioavailability 59 
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(18, 19).  In addition, the high barrier to genetic resistance, as well as the tolerability, safety 60 
profile, and potency of DRV - when administered in combination with a low-dose of either RTV 61 
(DRV/r), or COBI (DRV/c) - have made these fixed-dose combinations important options for the 62 
treatment of HIV-patients (20-22). 63 
 64 
Previous studies have demonstrated markedly reduced exposure of RTV-boosted PIs, 65 
including atazanavir (ATV) (12), indinavir (IDV) (13), and lopinavir (LPV) (14), as well as an 66 
increased risk of hepatotoxicity when RIF is co-administered with these drugs in healthy 67 
volunteers.  For this reason, studies aimed at investigating DDIs between DRV/r and RIF in 68 
HIV-negative subjects have not been undertaken.  Similarly, the extent of the DDI between 69 
DRV/c and RIF remains unknown.  A recent population PK (pop-PK) analysis showed that it 70 
was possible to offset the effects of RIF on DRV Ctrough by increasing the dose of DRV/r 71 
administered (23); raising the possibility that RTV may overcome potential DDIs between DRV 72 
and RIF in vitro and in vivo.  The aim of the present study was to quantify - using an in vitro 73 
model - the extent of DDIs arising from co-incubation of RIF with either RTV or COBI, by 74 
specifically measuring the apparent intrinsic clearance (CLint.app.) of DRV by primary human 75 
hepatocytes. 76 
77 
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MATERIALS AND METHODS 78 
Chemicals.  DRV (Cat. No.: S1620) and COBI (Cat. No.: S2900) were purchased from 79 
Selleckchem (Munich, Germany).  RIF (Cat. No.: R3501), RTV (Cat. No.: SML0491), 80 
potassium phosphate monobasic (Cat. No.: P0662), Hanks’ balanced salt solution (Cat. No.: 81 
H8264), methanol (Cat. No.: 34860), and acetonitrile (Cat. No.: 34967) were purchased from 82 
Sigma-Aldrich (Poole, UK).  Orthophosphoric acid (Cat. No.: 153154D) was purchased from 83 
VWR (Lutterworth, UK). HPLC-grade water was produced by an ELGA PureLab system 84 
(Veolia Water Technologies, High Wycombe, UK). 85 
Primary Hepatocytes.  Cryopreserved primary human hepatocytes were purchased from Life 86 
Technologies (Cat. No.: HMCPIS; Inchinnan, Scotland).  Hepatocytes from a total of four 87 
donors were used (Table 1). 88 
Stock Solutions.  Stock solutions of COBI, DRV, RIF and RTV were freshly prepared in 100% 89 
(v/v) methanol at concentrations 6443, 1684.3, 15000 and 6935.4 µM respectively. Prior to use 90 
in experiments, all stock solutions were sterile-filtered through a Millex 0.22 µm 91 
polyethersulfone membrane (Millipore, Cat. No.: SLGP033RS; Watford, UK), and were either 92 
used immediately, or were stored at -20 °C for up to five days prior to use. 93 
Concentrations of drugs used in this study.  Primary cryopreserved human hepatocytes were 94 
treated with a range of concentrations of test compounds - COBI (0.13—12.76 µM), RIF (0.50—95 
20.00 µM) and RTV (0.01—10.00 µM) - spanning the therapeutic plasma concentration range  96 
in humans as determined from clinical PK data (24), (25).  The concentration of DRV used in 97 
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experiments (5 μM), was selected from a value within the therapeutic range of DRV, as obtained 98 
from clinical PK data (18). 99 
Culture of Primary Human Hepatocytes.  Primary cryopreserved human hepatocytes were 100 
thawed in Cryopreserved Hepatocyte Recovery Medium (CHRM
®
, Life Technologies, Cat. No.: 101 
CM7000) and were re-suspended in Williams’ Medium E (WME) plating medium (WME Life 102 
Technologies, Cat. No.: A1217601, supplemented with Hepatocyte Plating Supplement Pack, 103 
Life Technologies, Cat. No.: CM3000).  Cell viability was determined using a NucleoCounter
®
 104 
NC-100™ (Sartorius Ltd., Epsom, UK). Viable cells were plated on collagen-coated 96-well cell 105 
culture plates (Life Technologies, Cat. No.: CM1096) at a density of 6.5 x 10
4
 cells per well in 106 
110 µl of WME plating medium.  Hepatocytes were incubated in a humidified incubator at 37 °C 107 
containing 5% (v/v) CO2 for five hours prior to removal of the WME plating medium, and 108 
overlaying the hepatocyte monolayer with 70 µl per well of Geltrex™ LDEV-Free Reduced 109 
Growth Factor Basement Membrane Matrix (Life Technologies, Cat. No.: A1413202) diluted in 110 
WME incubation medium (WME Life Technologies, Cat. No.: A1217601, supplemented with 111 
Hepatocyte Maintenance Supplement Pack, Life Technologies, Cat. No.: CM4000) to a final 112 
concentration of 0.35 mg/ml.  Cells were then incubated in a humidified incubator at 37 °C 113 
containing 5% (v/v) CO2 for 24 hours, prior to removal of the WME incubation medium and 114 
replacement with 110 µl of fresh WME incubation medium containing test compounds: COBI 115 
(0.128—12.76 µM), RTV (0.01—10 µM), RIF (0.5—20 µM) or methanol (0.3% v/v; vehicle 116 
control).  At 24 hours, and 48 hours post-initial treatment, WME incubation medium was 117 
removed, and replaced with fresh WME incubation medium containing test compounds.  At 72 118 
7 
 
hours post-initial treatment cells were treated with test compounds together with DRV (5 µM) 119 
for 60 minutes. 120 
Quantification of Darunavir by HPLC-UV.  Following 60 minutes of incubation of 121 
hepatocytes with test compounds together with 5 µM DRV, 100 µl of WME incubation medium 122 
was removed from each well and was transferred to Corning
® 
Pyrex
®
 75 x 12 mm borosilicate 123 
glass tubes (Appleton-Woods, Cat. No.: KC350) containing 300 µl of 100% acetonitrile.  124 
Standards and quality control samples were prepared in WME incubation medium and were 125 
treated in the same way. All samples were then vortexed for five seconds, and were dried in a 126 
Jouan RC10.22 vacuum centrifuge for six hours at room temperature (18—25°C). After drying, 127 
samples were re-constituted in 330 µl of 20% (v/v) acetonitrile and 80% (v/v) H2O. One hundred 128 
microlitres of the resultant suspension was used to quantify DRV by HPLC-UV. 129 
Chromatographic separation of DRV was achieved using a Waters Atlantis T3 (4.6 x 100 130 
mm, 3 μm) column (Waters, Elstree, UK) equipped with a 10 x 4 mm, 3 µm Fortis C18 Guard 131 
(Fortis™ Technologies Ltd., Chester, UK).  A Dionex P680 HPLC pump, Dionex ASI-100 132 
automated sample injector and a Dionex UVD170U UV detector (Thermo Fisher Ltd., Hemel-133 
Hempstead, UK) were used.  Mobile phases C (25 mM KH2PO4, pH 3.3/orthophosphoric acid) 134 
and D (100% acetonitrile) were used in a step-gradient elution as follows: 70% C/30% D from 135 
0.0 to 1.5 min, 35% C/65% D from 1.5 to 7.0 min, 20% C/80% D from 7.0 to 9.5 min and 70% 136 
C/30% D from 9.5 to 12.5 min.  Elution was carried out at room temperature (18—25°C), and 137 
the flow rate was maintained at 1.00 ml/min. Chromatograms were analysed and DRV was 138 
quantified at 267 nm using Chromeleon software (version 6.8; Thermo Fisher Ltd.). Each 139 
experimental condition was assessed in triplicate.  The lower limit of detection (LOQ) of DRV 140 
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was determined to be 0.156 µM.  The assay was linear between 0.156 µM and 10 µM (upper 141 
LOQ).  The mean coefficient of variability (CV) of intra-day precision was 2.6%, whilst the 142 
mean CV of intra-day accuracy was 2.0%.  The mean CV of inter-day precision was 2.2%, and 143 
the mean CV of inter-day accuracy was 1.2%.  The mean recovery of DRV from WEM was 144 
96.1%. 145 
Calculation of CLint.app.of Darunavir in Hepatocytes.  Apparent intrinsic clearance (CLint.app.) 146 
of DRV was calculated based on a method described previously (26).  This is summarised in 147 
Equation 1: 148 
Equation 1:   CLint.app. = (ln2/in vitro t1/2) x (µl incubation volume/10
6
 hepatocytes) 149 
Results were expressed as the mean ± SD (μl/min/106 hepatocytes) of a total of three 150 
donors per condition tested.    Three biological replicates were quantified per condition tested, 151 
using hepatocytes obtained from three separate donors in each case. 152 
Data and Statistical Analysis.  Statistical analyses were carried out using IBM
®
 SPSS
®
 153 
Statistics (Version 22; IBM Corporation, Armonk, NY, USA).  All data were assessed for 154 
normality using a Shapiro–Wilk test.  Univariate and stepwise-elimination multivariate linear 155 
regression analyses were conducted to characterise the influence of co-incubating primary 156 
human hepatocytes with various concentrations of RTV or COBI together with RIF on DRV 157 
CLint.app  Effective concentration (EC50) was calculated using GraphPad Prism
®
 (Version 5; 158 
GraphPad Software, Inc. La Jolla, CA, USA). 159 
160 
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RESULTS 161 
Assessment of the CLint.app. of Darunavir Following Combination Incubation of Primary 162 
Human Cryopreserved Hepatocytes with Ritonavir and Rifampicin.  Primary human 163 
hepatocytes are commonly used as a tool to predict hepatic metabolic clearance of xenobiotics 164 
and DDIs in vitro (27, 28).  Using this model system, the CLint.app. of DRV was initially 165 
calculated under control conditions in which hepatocytes (Lot HU1399, Lot HU1587 and Lot 166 
HU1621) were incubated with DRV alone.  Under these conditions, mean DRV CLint.app. was 167 
10.5 ± 3.8 μl/min/106 hepatocytes (n=3).  Incubation of hepatocytes with RIF was sufficient to 168 
markedly increase DRV CLint.app. at each concentration of RIF tested (0.5—20 µM) (Fig. 1).  The 169 
maximal RIF-induced increase (1.9 ± 0.3-fold; n=3) in DRV CLint.app. was observed with 10 µM 170 
RIF (Fig. 1).  171 
Co-incubation of RIF with RTV reduced 10 μM RIF-induced increases in CLint.app. in a 172 
RTV concentration-dependent manner (Fig. 1).  Notably, RTV (1 μM) was sufficient to 173 
overcome the effect of 10 μM RIF on DRV CLint.app., reducing DRV CLint.app. to 0.78 ± 0.25-fold 174 
– equivalent to -22% when compared to control levels in which cells were treated with DRV 175 
alone (n=3; Fig. 1).  Increasing RIF concentrations above 10 µM (12.5—20 μM) did not impact 176 
the effectiveness of RTV to overcome RIF-elevated DRV CLint.app. (Fig. 1).  Specifically, 1 μM 177 
RTV lowered 12.5 μM RIF-induced and 20 μM RIF-induced DRV CLint.app. by 55% and  47%, to 178 
(8.6 ± 3.2 μl/min/106 hepatocytes; n=3) and (8.8 ± 3.4 μl/min/106 hepatocytes; n=3), 179 
respectively. 180 
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Assessment of the CLint.app. of Darunavir Following Combination Incubation of Primary 181 
Human Cryopreserved Hepatocytes with Cobicistat and Rifampicin.  In a separate set of 182 
experiments, human hepatocytes from three individual donors (Lot HU1399, Lot HU1574 and 183 
Lot HU1587) were used to determine the effects of incubating rifampicin together with cobicistat 184 
on DRV CLint.app..  Under control conditions, where primary human cryopreserved hepatocytes 185 
were incubated with DRV alone, DRV CLint.app. was 13.2 ± 1.8 μl/min/10
6
 hepatocytes, (n=3).  186 
Incubation of hepatocytes with RIF (0.5—20 µM), induced a mean increase in DRV CLint.app. of 187 
55.8%.  In cells treated with 1 µM RIF, co-incubation with the lowest concentration of COBI 188 
tested (0.42 µM) was effective in lowering RIF-induced DRV CLint.app. by 36.9%, yielding a 189 
DRV CLint.app. of 12.2 ± 2.8 μl/min/10
6
 hepatocytes (n=3).  Hepatocytes treated with 10 µM RIF 190 
exhibited a DRV CLint.app. of 21.6 ± 2.6 μl/min/10
6
 hepatocytes (n=3).  COBI induced a 191 
concentration-dependent attenuation of the DRV CLint.app., elicited by 10 µM RIF, with 1.28 µM 192 
COBI being sufficient to lower DRV CLint.app to 11.6 ± 2.6 μl/min/10
6
 hepatocytes (n=3), 13% 193 
below DRV control levels (Fig. 2).  COBI was also effective at reducing CLint.app. elevations 194 
induced by higher concentrations of RIF, as co-incubation with 1.28 µM COBI reduced 20 μM 195 
RIF-elevated DRV CLint.app. by 46% (12.4 ± 3.9 μl/min/10
6
 hepatocytes; n=3). 196 
197 
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Comparison of Cobicistat- and Ritonavir-mediated Reduction of Rifampicin-Induced 198 
Darunavir CLint.app..  To compare the  relative effectiveness of RTV and COBI to attenuate 199 
RIF-induced increases in DRV CLint.app., the percentage inhibition of 10 µM RIF-induced 200 
elevations in DRV CLint.app. achieved by co-incubation with either COBI (0.13—12.76 µM), or 201 
RTV (0.1—10 µM), was determined in comparison to control conditions where cells were 202 
treated with 10 µM RIF alone (Fig. 3).  The effective concentration 50% of maximum response 203 
(EC50) of COBI and RTV calculated from the percentage-change in DRV CLint.app. under these 204 
conditions was 1.5 µM for COBI and 2.6 µM for RTV (Fig. 3).  In addition, the maximal 205 
inhibition of 10 µM RIF-induced elevations achieved by COBI and RTV were different, with 206 
RTV resulting in a 69.5% inhibition of 10 µM RIF-induced  increases in DRV CLint.app., whilst  207 
COBI-mediated reduction in 10 µM RIF-induced  increases in DRV CLint.app. was 56.9% 208 
(P=0.05). 209 
  Following data normalisation, linear regression analysis of the effects of RTV and 210 
COBI in combination with RIF at each concentration tested on the percentage change in DRV 211 
CLint.app. showed an association between log10 RTV concentrations, and log10 COBI 212 
concentrations and percentage inhibition of RIF-induced DRV CLint.app. of β = -94 (95% CI = -213 
108 to -80; P=0.0001), and β = - 61 (95% CI = -73 to -49; P=0.0001), respectively.  Conducting 214 
linear regression analysis of the effects of RIF on DRV CLint.app. revealed that RIF exerted a 215 
similar effect on DRV CLint.app. in the two independent sets of RTV and COBI experiments, with 216 
a positive association observed between RIF concentration and DRV CLint.app. of β =  22 (95% CI 217 
= 9 to 35; P=0.001)  and β = 16 (95% CI = 5 to 27; P=0.004) in the RTV experiments, and 218 
COBI experiments, respectively. 219 
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DISCUSSION AND CONCLUSIONS 220 
RIF strongly induces the expression of metabolic enzymes such as CYP3A4 (29-31), and can 221 
also induce the activity of drug transporters (32).  Collectively, this can result in clinically-222 
relevant DDIs in patients that receive RIF together with other medications (11, 33).  These DDIs 223 
present challenges for the treatment of HIV-TB patients, as several therapeutic options are 224 
contraindicated due to known DDIs (10), whilst other potentially viable treatment regimens may 225 
either be delayed, or avoided completely due to hypothetical DDIs that are predicted to occur 226 
between anti-TB drugs and ARVs such as PIs.  For example, co-administering the standard-dose 227 
of any PI with RIF is currently contraindicated under WHO guidelines (15), but the extent of 228 
potential DDIs between RIF and PIs has not been determined for all PIs, including DRV.  Co-229 
administering dose-adjusted LPV/r, or SQV/r together with RIF is indicated, albeit with the 230 
caveat that high levels of toxicity can occur.  This raises the possibility that administering other 231 
PIs, such as RTV-, or COBI-boosted DRV, together with RIF may also be feasible.  The present 232 
study addresses this issue by providing the first experimental insight into the effects of co-233 
incubating either RTV, or COBI, together with RIF on DRV CLint.app. in a human hepatocyte-234 
based in vitro model of drug metabolism. 235 
Utilisation of human hepatocytes to predict hepatic metabolic clearance of xenobiotics is 236 
well-established (27, 28).  In this study, incubation of cryopreserved human hepatocytes with 237 
RIF increased DRV CLint.app. (Fig. 1 and Fig. 2).  This is likely due to induction of CYP3A4 (17, 238 
34), although the effects of RIF on transporters may also be important (28).  Uptake transporters 239 
such as organic anion transporting polypeptide isoform 1B1 (OATP1B1) (35), and efflux 240 
transporters such as P-gp (36), have been shown to play a role in PI elimination, and therefore 241 
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may also be relevant in the DDIs between RIF and COBI-, or RTV-boosted DRV.  Indeed, RIF 242 
has been shown to inhibit OATP1B1 (37), and DRV uptake by OATP1B1 and OATP1B3 in 243 
transfected CHO cells has been reported (38).  Utilising a pop-PK-model, it has been suggested 244 
that OATP3A1 polymorphisms are associated with DRV PK (39), in addition, a recent 245 
physiologically-based PK (PBPK) modelling-based study that investigated the PK of DRV/r 246 
during pregnancy has also suggested a role for hepatic transporters in DRV disposition (40). 247 
Co-incubation of human cryopreserved hepatocytes with COBI and RIF, or RTV and RIF 248 
- using concentrations spanning the in vivo therapeutic range of these compounds - revealed that 249 
both RTV and COBI could reduce RIF-enhanced DRV CLint.app. in a concentration-dependent 250 
manner (Fig. 1 and Fig. 2).  RTV was more effective than COBI at attenuating the RIF-induced 251 
increase in DRV CLint.app., with RTV exhibiting a lower EC50 compared to COBI, whilst RTV 252 
also achieved greater maximal inhibition of the 10 µM RIF-induced increase in DRV CLint.app. 253 
compared to COBI (Fig. 3).  Furthermore, regression analysis revealed a stronger effect of RTV 254 
in comparison to COBI for their relative contribution in reducing RIF-induced increases in DRV 255 
CLint.app..  Due to the more recent approval of COBI, data regarding potential DDIs between 256 
COBI and other medications is more limited than with RTV.  The expected differential DDI 257 
profiles of COBI and RTV when administered with co-medications have been recently reviewed 258 
(41, 42).  RTV and COBI both serve as strong inhibitors of CYP3A4 in vivo (43, 44); however, 259 
RTV is also known to induce the expression of various metabolic enzymes, including CYP3A4, 260 
in primary human hepatocytes in vitro (30).  Very few studies aimed at investigating the relative 261 
effects of COBI as an inducer of metabolic enzyme expression have thus far been conducted, 262 
although it has been suggested that the induction potential of COBI is less than that of RTV (45), 263 
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and that COBI is not expected to induce CYP3A4 expression (46).  It was recently suggested that 264 
hepatic uptake of RTV occurs chiefly by passive diffusion (47).  In addition, RTV has been 265 
shown to induce expression of the efflux transporters P-gp (30), and multidrug resistance-266 
associated protein 1 (MRP1; ABCC1) in primary human hepatocytes in vitro (30).  DRV is a 267 
substrate of P-gp (48) and OATP1A2 and OATP1B1 (35), whilst RTV appears to inhibit P-gp 268 
(48), as well as OATP1B1 and OATP1B3 (38), in vitro.  At the same time, RIF has been 269 
described as an inhibitor of various OATPs in vitro, including OATP1B1 and OATP1B3 (38).  270 
In addition, chronic exposure to RIF has been shown to exert an inhibitory effect on P-gp in vitro 271 
(49).  It remains to be seen therefore what the net contribution of transporters such as OATP1B1, 272 
OATB1B3 and P-gp may be on plasma levels of DRV in vivo, especially when DRV is 273 
administered in combination with other compounds such as RIF. 274 
The PK profiles of DRV/r (800/100 mg, qd) and DRV/c (800/150 mg, qd) in HIV-275 
infected patients are broadly similar (50, 51).  However, in a study conducted in healthy 276 
volunteers, it has been reported that DRV Cmin values were 30% lower in individuals treated with 277 
DRV/c compared with individuals treated with DRV/r (52).  In addition, PK analysis of the PI 278 
tipranavir (TPV), when administered in combination with COBI or RTV in healthy volunteers, 279 
showed that TPV AUC, Cmax and Ctau levels were significantly lower with COBI compared to 280 
RTV (53).  Collectively, these studies suggest that the pharmacoenhancment with COBI is not 281 
always equal to that of RTV.   282 
Whilst no studies have been conducted investigating the effects of co-administering 283 
either DRV/r or DRV/c with RIF on DRV bioavailability, it has recently been shown using a 284 
pop-PK modelling approach that administering dose-adjusted DRV/r (1600/200 mg qd; 800/100 285 
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mg bid; or 1200/150 mg bid) can potentially overcome the effects of RIF on DRV Ctrough, albeit 286 
with the caveat that RTV-related side-effects may occur and that a higher pill burden would be 287 
required  (23).  These in silico findings are in general agreement with the in vitro outcomes of 288 
the present study.  In addition, it is interesting to speculate that given the observation that low 289 
concentrations of either RTV or COBI could overcome RIF-induced elevations in DRV CLint.app., 290 
increasing the dose of the pharmacoenhancer may not be necessary to achieve therapeutic 291 
concentrations of DRV in combination with RTV or COBI.  Even so, extrapolating the in vivo 292 
significance of in vitro data presents multiple challenges (54, 55), and it is difficult to directly 293 
infer how these results may translate in vivo.  For example, increasing the dose of RTV in 294 
combination with a given PI is not always sufficient to overcome the effects of RIF. Indeed, a 295 
study of the effects of RIF on the steady-state PK of ATV with RTV in healthy volunteers 296 
showed that administering ATV/RTV 300/100 mg, ATV/RTV 300/200 mg, and ATV/RTV 297 
400/200 mg was insufficient to completely overcome the inductive potential of RIF 600 mg (12).  298 
In an effort to better understand the absorption, distribution, metabolism and elimination of 299 
various compounds, the use of PBPK models has recently gained popularity (56).  Various PBPK 300 
models have been developed that have proven useful in predicting the effects of administering 301 
ARVs in HIV patients with co-morbidities (57).  Indeed, a recent study described the 302 
development of a PBPK model for predicting clinical DDIs from RIF-based in vitro human 303 
hepatocyte data (58), and it is therefore hoped that the data presented herein will be of use in the 304 
development of PBPK models to predict the effects of co-administering boosted PIs with anti-TB 305 
drugs. 306 
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In conclusion, the results presented herein provide insight into the relative effects of RTV 307 
and COBI as pharmacoenhancers of DRV in the presence of RIF in an in vitro model of drug 308 
metabolism, which can be used in conjunction with PBPK models to rationalise future strategies 309 
aimed at optimising treatment regimens.  Further work should aim to elucidate the mechanisms 310 
that give rise to the differential inhibitory potential of COBI and RTV demonstrated herein, as 311 
well as to validate these results in vivo.  Future studies should also aim to further evaluate the 312 
effects of COBI and RTV on gene expression, as well as the effects of these compounds on the 313 
expression and activity of various drug transporters in vitro.  Finally, it would also be of interest 314 
to use this model system to evaluate potential DDIs that may occur between RIF and RTV, or 315 
COBI, in combination with other PIs, or with other co-medications. 316 
317 
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FIGURES AND FIGURE LEGENDS 500 
FIGURE 1 501 
 502 
Figure 1: Effects of rifampicin alone, or in combination with ritonavir, on mean DRV 503 
CLint.app. in primary human hepatocytes in vitro.  Cryopreserved primary human hepatocytes 504 
were incubated with rifampicin (RIF; 0.5—20 µM), hatched bars; or with ritonavir (RTV; 0.01–505 
10 µM) and RIF (0.5—20 µM), grey bars; each day for 72 hours.  All cells were then incubated 506 
with RIF (0.5—20 µM), or RIF (0.5—20 µM) together with RTV (0.01–10 µM) as described 507 
above, together with darunavir (DRV; 5 μM), black bar, for 60 minutes.  Control cells were 508 
treated with DRV (5 μM) alone for 60 minutes.    The results shown represent the mean DRV 509 
CLint.app. from three biological replicates measured in hepatocytes from three independent donors 510 
(Lot HU1399, HU1587 and HU1621).  Error bars: SD.511 
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FIGURE 2  512 
 513 
Figure 2: Effects of rifampicin alone, or in combination with cobicistat, on mean DRV 514 
CLint.app. in primary human hepatocytes in vitro. Cryopreserved primary human hepatocytes 515 
were incubated with rifampicin (RIF; 0.5—20 µM), hatched bars; or with cobicistat (COBI; 516 
0.13–12.76 µM)  and RIF (0.5—20 µM), grey bars; each day for 72 hours.  All cells were then 517 
incubated with RIF (0.5—20 µM), or RIF (0.5—20 µM) together with cobicistat (COBI; 0.13–518 
12.76 µM) as described above, together with darunavir (DRV; 5 μM), black bar, for 60 minutes.  519 
Control cells were treated with DRV (5 μM) alone for 60 minutes.    The results shown represent 520 
the mean DRV CLint.app. from three biological replicates measured in hepatocytes from three 521 
independent donors (Lot HU1399, HU1574 and HU1587).  Error bars: SD. 522 
523 
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FIGURE 3 524 
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Figure 3: Relative effectiveness of COBI and RTV at lowering RIF-induced DRV CLint.app..  526 
Line graph shows the percentage inhibition of 10 µM rifampicin (RIF)-induced elevations in 527 
DRV CLint.app. in cryopreserved primary human hepatocytes following co-incubation with 528 
ritonavir (RTV; 0.1—10 µM; donors HU1399, HU1587 and HU1621), or cobicistat (COBI; 529 
0.13—12.76 µM, donors HU1399, HU1574 and HU1587) in combination with RIF (10 µM) for 530 
72 hours.  Each condition was tested in triplicate in each donor.  RTV and COBI concentrations 531 
are presented as log10 (µM value-0.001).  Error bars: SD. 532 
533 
RTV EC50:   1.538 µM 
COBI EC50: 2.582 µM 
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TABLES 534 
TABLE 1  535 
Table 1: Donor Demographic Information for Cryopreserved Primary Human Hepatocytes Used 536 
Donor Sex Race Age Medications Drug Use 
HU1399 Female Caucasian 72 
Insulin glargine: 10 units qd; 
Metoprolol: 100 mg qd; Lisinopril 
hydrochlorothiazide: 20/12.5 mg qd; 
Calcium + Vitamin D: 500 mg qd; 
Multivitamin: qd; Aspirin: 81 mg qd 
Historic long-
term tobacco use 
HU1574 Male Caucasian 70 
Atorvastatin: 80 mg qd; Lisinopril: 5 
mg qd.; Aspirin: 81 mg qd; 
Tamsulosin: 4 mg qd 
None reported 
HU1587 Female Caucasian 43 
Vitamin D oral; Multivitamin oral; 
Calcium + Vitamin D + Vitamin K 
None reported 
HU1621 Male Caucasian 66 Pazopanib: 800 mg qd 
Rare alcohol 
use. Historic 
tobacco use 
 537 
